SK bioscience has shipped approximately 440,000 doses of SKYCellflu to Biogenetech in Thailand from its vaccine manufacturing facility 'L HOUSE' in Andong, South Korea.
SK bioscience Breaks Ground on Manufacturing Facility Expansion
SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine
SEONGNAM, South Korea, Sept. 8, 2023 /PRNewswire/ -- SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that Ana Brnabi?, Prime Minister of the Republic of Serbia (Serbia) has visited the SK bioscience headquarters and signed a memorandum of understanding (MOU) with the company to establish a strategic partnership in vaccine development and manufacturing between the two countries.
South Korea-based SK bioscience has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.
SEONGNAM, South Korea, Aug. 8, 2023 /PRNewswire/ -- SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board of directors has decided to make an equity investment in Novavax, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, securing 6.5 million shares of common stock through a private placement.
Aug 8 (Reuters) - SK Bioscience (302440.KS) is taking a roughly 7% stake in Novavax (NVAX.O) in lieu of some payment owed to the South Korean biotech company, giving the cash-strapped COVID-19 vaccine maker some breathing room.
SK bioscience signed a memorandum of understanding with Thailand’s Government Pharmaceutical Organization to help develop the country’s vaccine manufacturing sector, with the partners aiming to turn the country into a sterile injection hub for Southeast Asia.
SEONGNAM, South Korea, June 29, 2023 /PRNewswire/ -- SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410' (also known as SP0202), evaluating its safety and immunogenicity.
SK bioscience, a global innovative vaccine and biotech company, signed a research collaboration agreement with the Doherty Institute for influenza research.